Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund

No definition available.

Name:	rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights and Obligations, Proceeds From Sale

+ References

No definition available.

+ Details

Name:	rprx_CollaborativeArrangementRightsAndObligationsProceedsFromSale
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Debt Securities, Available-For-Sale, Future Draw Amount

+ References

No definition available.

+ Details

Name:	rprx_DebtSecuritiesAvailableForSaleFutureDrawAmount
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Debt Securities, Available-For-Sale, Number Of Additional Funding Tranches

+ References

No definition available.

+ Details

Name:	rprx_DebtSecuritiesAvailableForSaleNumberOfAdditionalFundingTranches
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Debt Securities, Available-For-Sale, Number Of Tranches No Longer Available

+ References

No definition available.

+ Details

Name:	rprx_DebtSecuritiesAvailableForSaleNumberOfTranchesNoLongerAvailable
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Long Term Funding Partnership, Amount

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipAmount
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple
Namespace Prefix:	rprx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Long Term Funding Partnership, Number Of Quarters

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipNumberOfQuarters
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Long Term Funding Partnership, Number of Tranches

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipNumberOfTranches
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Long Term Funding Partnership, Number Of Tranches Available For Draw

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipNumberOfTranchesAvailableForDraw
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Long Term Funding Partnership, Royalty Installment Repayments, Amount

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipRoyaltyInstallmentRepaymentsAmount
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Long Term Funding Partnership, Royalty Percentage On Annual Net Sales

+ References

No definition available.

+ Details

Name:	rprx_LongTermFundingPartnershipRoyaltyPercentageOnAnnualNetSales
Namespace Prefix:	rprx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Consecutive Quarterly Payments

+ References

No definition available.

+ Details

Name:	rprx_NumberOfConsecutiveQuarterlyPayments
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B

+ Details

Name:	us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=rprx_CytokineticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rprx_DevelopmentFundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rprx_Phase3TrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rprx_CommercialLaunchFundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rprx_LongTermFundingPartnershipTrancheAxis=rprx_TranchesOneFourFiveAndSixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rprx_LongTermFundingPartnershipTrancheAxis=rprx_TrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rprx_LongTermFundingPartnershipTrancheAxis=rprx_TrancheThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rprx_LongTermFundingPartnershipTrancheAxis=rprx_TrancheSevenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rprx_LongTermFundingPartnershipTrancheAxis=rprx_TranchesOneFourFiveSixAndSevenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rprx_CytokineticsFundingCommitmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rprx_MorphoSysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rprx_DevelopmentFundingBondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Available for Sale Debt Securities - Narrative (Details) $ in Millions	1 Months Ended			3 Months Ended	12 Months Ended
	Jan. 31, 2025 USD ($)	May 31, 2024 USD ($) tranche quarter payment	Sep. 30, 2022 USD ($)	Dec. 31, 2025 USD ($) tranche	Dec. 31, 2025 USD ($)
Cytokinetics
Debt and Equity Securities, FV-NI [Line Items]
Long term funding partnership, amount		$ 50
Installment repayments, percentage of amount drawn		1.5
Cytokinetics \| Development Funding
Debt and Equity Securities, FV-NI [Line Items]
Long term funding partnership, amount		$ 100
Long term funding partnership, royalty installment repayments, amount		$ 100
Long term funding partnership, royalty percentage on annual net sales		2.00%
Number of quarters \| quarter		18
Installment repayments, percentage of amount drawn		2.4
Cytokinetics \| Development Funding \| Phase 3 Trial
Debt and Equity Securities, FV-NI [Line Items]
Number of quarters \| quarter		22
Installment repayments, percentage of amount drawn		2.3
Cytokinetics \| Commercial Launch Funding
Debt and Equity Securities, FV-NI [Line Items]
Long term funding partnership, amount		$ 525
Number of additional funding tranches \| tranche		2
Long term funding partnership, number of tranches \| tranche		7
Cytokinetics \| Commercial Launch Funding \| Tranches One, Four, Five and Six
Debt and Equity Securities, FV-NI [Line Items]
Long term funding partnership, amount					$ 275
Cytokinetics \| Commercial Launch Funding \| Tranche 2
Debt and Equity Securities, FV-NI [Line Items]
Number of tranches no longer available \| tranche		2
Cytokinetics \| Commercial Launch Funding \| Tranche 3
Debt and Equity Securities, FV-NI [Line Items]
Number of tranches no longer available \| tranche		3
Cytokinetics \| Commercial Launch Funding \| Tranche 7
Debt and Equity Securities, FV-NI [Line Items]
Number of tranches available for draw \| tranche				7
Cytokinetics \| Commercial Launch Funding \| Tranches One, Four, Five, Six, And Seven
Debt and Equity Securities, FV-NI [Line Items]
Installment repayments, percentage of amount drawn		1.9
Number of consecutive quarterly payments \| payment		34
Cytokinetics \| Commercial Launch Funding \| Cytokinetics Funding Commitments \| Tranche 7
Debt and Equity Securities, FV-NI [Line Items]
Future draw amount				$ 175
MorphoSys \| Development Funding
Debt and Equity Securities, FV-NI [Line Items]
Collaborative commitment to fund collaborative arrangement			$ 300
Development fund bond
Debt and Equity Securities, FV-NI [Line Items]
Proceeds from sale	$ 511